<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122807">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02051972</url>
  </required_header>
  <id_info>
    <org_study_id>LCP005</org_study_id>
    <nct_id>NCT02051972</nct_id>
  </id_info>
  <brief_title>The LEADLESS Observational Study</brief_title>
  <official_title>Nanostim Study for a Leadless Cardiac Pacemaker System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Austria : Federal Ministry for Labour, Health, and Social Affairs</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to confirm clinical performance and safety of the Nanostim
      leadless cardiac pacemaker system within its intended use and according to its instructions
      for use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Complication free-rate</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A complication is defined as a serious adverse device effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of observed complication rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A complication is defined as a serious adverse device effect</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complication-free rate</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A complication is defined as a serious adverse device effect</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Indications for VVI(R) Pacemaker</condition>
  <arm_group>
    <arm_group_label>Indicated for a VVI(R) pacemaker</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implanted with a Nanostim leadless pacemaker system</intervention_name>
    <arm_group_label>Indicated for a VVI(R) pacemaker</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are at least 18 years old and who are indicated for a VVI(R) pacemaker
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have one of the following clinical indications: Chronic atrial
             fibrillation  with 2 or 3° AV or bifascicular bundle branch block (BBB block) ; or
             Normal sinus rhythm with 2º or 3° AV or BBB block  and a low level of physical
             activity or short expected lifespan (but at least one year); or Sinus bradycardia
             with infrequent pauses or unexplained syncope with EP findings; and

          -  Subject ≥18 years of age; and

          -  Subject has life expectancy of at least one year; and

          -  Subject is not enrolled in another clinical investigation with a treatment arm or
             that could confound the results of this study; and

          -  Subject is willing to comply with clinical investigation procedures and agrees to
             return for all required follow-up visits, tests, and exams; and

          -  Subject has been informed of the nature of the study, agrees to its provisions and
             has provided written informed consent, approved by the EC; and

          -  Subject is not pregnant and does not plan on getting pregnant during the course of
             the study.

        Exclusion Criteria:

          -  Known pacemaker syndrome, have retrograde VA conduction or suffer a drop in arterial
             blood pressure with the onset of ventricular pacing; or

          -  Hypersensitivity to &lt; 1 mg of dexamethasone sodium phosphate; or

          -  Mechanical tricuspid valve prosthesis; or

          -  Pre-existing pulmonary arterial (PA) hypertension or significant
             physiologically-impairing lung disease; or

          -  Pre-existing ventricular pacing or defibrillation leads; or

          -  Current implantation of either conventional or subcutaneous implantable cardioverter
             defibrillator (ICD) or cardiac resynchronization therapy (CRT); or

          -  Presence of implanted vena cava filter; or

          -  Evidence of thrombosis in one of the veins used for access during the procedure; or

          -  Presence of implanted leadless cardiac pacemaker
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Sperzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinick GmbH, Bad Nauheim, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asish Oza</last_name>
    <phone>+1 818 493 3648</phone>
    <email>aoza@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Ducloux</last_name>
    <phone>+32 2 774 67 09</phone>
    <email>pducloux@sjm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Neuzil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Johannes Sperzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reinoud Knops, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>6010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Garcia Guerrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge Silvestre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
